Anzeige
Mehr »
Donnerstag, 03.12.2020 Börsentäglich über 12.000 News von 648 internationalen Medien
+++Übernahmekampf: Hammer-Nachricht bei unserem Nevada-Goldwert+++
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YHA5 ISIN: US23283M1018 Ticker-Symbol: 296 
Stuttgart
03.12.20
19:17 Uhr
1,930 Euro
-0,150
-7,21 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CYTODYN INC Chart 1 Jahr
5-Tage-Chart
CYTODYN INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8701,96019:56

Aktuelle News zur CYTODYN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CYTODYN Aktie jetzt für 0€ handeln
15:05CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab14
MiCytoDyn says first patient enrolled for its Phase 2 clinical trial using leronlimab to treat NASH10
MiCytoDyn Inc.: CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH8
23.11.CytoDyn partners with The Foundation for AIDS Research to test leronlimab as researchers advance toward HIV cure16
23.11.NA Proactive news snapshot: CytoDyn, Humanigen, Killi, Great Panther Mining UPDATE…11
23.11.CytoDyn Inc.: CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research4
23.11.NA Proactive news snapshot: Algernon Pharmaceuticals, African Gold Group , CytoDyn, RideShare Rental …16
23.11.CytoDyn enlists 293 patients for second interim analysis of leronlimab in Phase 3 COVID-19 trial6
23.11.CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial10
23.11.CytoDyn Inc.: CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining ...11
17.11.NA Proactive news snapshot: Alpine 4 Technologies, HealthLynked, CytoDyn, Nemaura Medical UPDATE ...16
17.11.CytoDyn files protocol with FDA for Phase 2 leronlimab trial in 'long-hauler' coronavirus patients11
17.11.CytoDyn Files Protocol With FDA For Phase2 Trial For COVID-19 Patients With Long-Hauler Symptoms9
17.11.CytoDyn Inc.: CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms6
16.11.CytoDyn Inc. - 8-K, Current Report6
16.11.CytoDyn receives Canadian approval to file application for leronlimab as combination therapy for HIV14
16.11.CytoDyn Inc.: CytoDyn Announces Registration of Trademark for VYROLOGIX in Several Countries6
16.11.CytoDyn Inc.: Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy6
11.11.CytoDyn gets $25M in convertible debt deal to fund license applications, coronavirus trials for leronlimab36
11.11.CytoDyn secures $28.5M in convertible debt18
Seite:  Weiter >>
184 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,2,9